In this study, we demonstrated that FGFR1 amplification is an independent adverse prognostic factor in surgically resected ESCC, indicating that FGFR1 amplification may be a relevant therapeutic target in ESCC. This evidence concerns the gene FGFR1 and esophageal squamous cell carcinoma.